Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 166

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 166
---
 managerial insurance funds, and redeemed vacation      
 pay. This amount represents Israeli severance fund payments, managerial insurance funds, disability insurance, supplemental education 
 fund contribution and social securities. See discussion below under “Narrative Disclosure to Summary Compensation Table..             |

All other expenses.

The following table provides information
regarding each component of compensation for fiscal years 2024 and 2023 included in the “All Other Compensation” column in
the “Summary Compensation Table” above. Represents amounts paid in New Israeli Shekels (NIS) and converted at average exchange
rates for the year.

| Name         |     | Year |       |     | Automobile   
 and Related  
 Expenses (1) |       |     | Social   
 Benefits |        |     | Total |        |
|:-------------|:----|:-----|:------|:----|:-------------|------:|:----|:---------|-------:|:----|:------|-------:|
| David Akunis |     |      | 2024* |     |              |    ** |     | $        |  2,500 |     | $     |  2,500 |
| Inna Martin  |     |      | 2024* |     | $            | 7,000 |     | $        | 14,000 |     | $     | 21,000 |

| ** | Less than $1,000 |

| 1. | Leased automobile. |

| 2. | These are comprised of contributions by                                                      
 us to savings, health, severance, pension, disability and insurance plans generally provided 
 in Israel, including health, education, managerial insurance funds, and redeemed vacation    
 pay. This amount represents Israeli severance fund payments, managerial insurance funds,     
 disability insurance, supplemental education fund contribution and social securities.        |

<div align='center'>100</div>

EMPLOYMENT/CONSULTING AGREEMENTS

Narrative Disclosure to Summary Compensation Table

Our Board follows the following processes and
procedures for the consideration and determination of executive and director compensation:

In establishing compensation amounts for executives,
we seek to provide compensation that is competitive in light of current market conditions and industry practices. Accordingly, we will
generally review market data, which is comprised of proxy-disclosed data from peer companies and information from nationally recognized
published surveys for the biopharmaceutical industry, adjusted for size. The market data helps the committee gain perspective on the compensation
levels and